BR112022024294A2 - Bioconjugado shigella-tetravalente (shigella4v)". - Google Patents

Bioconjugado shigella-tetravalente (shigella4v)".

Info

Publication number
BR112022024294A2
BR112022024294A2 BR112022024294A BR112022024294A BR112022024294A2 BR 112022024294 A2 BR112022024294 A2 BR 112022024294A2 BR 112022024294 A BR112022024294 A BR 112022024294A BR 112022024294 A BR112022024294 A BR 112022024294A BR 112022024294 A2 BR112022024294 A2 BR 112022024294A2
Authority
BR
Brazil
Prior art keywords
shigella
shigella4v
bioconjugate
tetravalent
composition
Prior art date
Application number
BR112022024294A
Other languages
English (en)
Portuguese (pt)
Inventor
Edward Braun Martin
Follador Rainer
Jochen Kemmler Stefan
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112022024294A2 publication Critical patent/BR112022024294A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112022024294A 2020-06-18 2021-06-17 Bioconjugado shigella-tetravalente (shigella4v)". BR112022024294A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063040844P 2020-06-18 2020-06-18
US202063043883P 2020-06-25 2020-06-25
EP20182139 2020-06-25
EP20182138 2020-06-25
PCT/IB2021/055361 WO2021255684A1 (en) 2020-06-18 2021-06-17 Shigella-tetravalent (shigella4v) bioconjugate

Publications (1)

Publication Number Publication Date
BR112022024294A2 true BR112022024294A2 (pt) 2023-02-28

Family

ID=76502778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024294A BR112022024294A2 (pt) 2020-06-18 2021-06-17 Bioconjugado shigella-tetravalente (shigella4v)".

Country Status (8)

Country Link
US (1) US20230346902A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168040A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023530154A (cg-RX-API-DMAC7.html)
CN (1) CN115697396A (cg-RX-API-DMAC7.html)
BR (1) BR112022024294A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185719A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022016587A (cg-RX-API-DMAC7.html)
WO (1) WO2021255684A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026087718A1 (en) * 2024-10-23 2026-04-30 Institut Pasteur A multivalent shigella vaccine and methods of making and using thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
ES2535084T3 (es) 2005-05-11 2015-05-05 Eth Zurich Proteínas N-glicosiladas recombinantes procedentes de células procariotas
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
US9238830B2 (en) 2006-12-13 2016-01-19 The Governors Of The University Of Alberta Methods and systems for O-glycosylating proteins
SI2257307T1 (sl) 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
CN101569744A (zh) * 2009-01-20 2009-11-04 张鑫 一种细菌性痢疾多价疫苗
NO2501406T3 (cg-RX-API-DMAC7.html) 2009-11-19 2018-05-19
KR20150068998A (ko) * 2012-10-12 2015-06-22 글리코박신 아게 숙주 세포 변형 방법
EP2917351B1 (en) * 2012-11-07 2018-12-19 GlaxoSmithKline Biologicals S.A. Production of recombinant vaccine in e. coli by enzymatic conjugation
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
CN106659799B (zh) * 2014-07-25 2020-07-17 碧奥辛斯有限责任公司 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
CN114796472A (zh) * 2015-06-16 2022-07-29 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition

Also Published As

Publication number Publication date
EP4168040A1 (en) 2023-04-26
MX2022016587A (es) 2023-02-01
WO2021255684A1 (en) 2021-12-23
CN115697396A (zh) 2023-02-03
CA3185719A1 (en) 2021-12-23
US20230346902A1 (en) 2023-11-02
JP2023530154A (ja) 2023-07-13

Similar Documents

Publication Publication Date Title
Tobe et al. Activation of motility by sensing short-chain fatty acids via two steps in a flagellar gene regulatory cascade in enterohemorrhagic Escherichia coli
Hoffmann et al. The Yersinia pseudotuberculosis cytotoxic necrotizing factor (CNFY) selectively activates RhoA
EA202092003A1 (ru) Соединения для лечения болезни гентингтона
BR112022000216A2 (pt) Anticorpos direcionados a dll3 e usos dos mesmos
BR9915852A (pt) Conjugado de hapteno-portador para tratamento e prevenção do vìcio da nicotina
ES2156199T3 (es) Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma.
BR112023023671A2 (pt) Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
BR0211926A (pt) agentes para realçar a resposta imune
PE20110023A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
CY1118258T1 (el) Εντεροδιαλυτη συνθεση για την παρασκευη περιβληματος μαλακης καψουλας
DE602006017225D1 (de) Erbsenproteinzusammensetzung
HK1212249A1 (en) Bioconjugates comprising modified antigens and uses thereof
BR112022003046A2 (pt) Conjugados de il-15 e usos dos mesmos
CY1114716T1 (el) Ανασυσταθεντα επιφανειοδραστικα τα οποια διαθετουν βελτιωμενες ιδιοτητες
JOP20230057A1 (ar) تركيبات لقاح متعددة التكافؤ واستخداماتها
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
Wang et al. Protein changes in Trichinella spiralis muscle larvae in vitro induced by bovine bile
BR112014015390A8 (pt) vírus da estomatite vesicular para vacinas iniciais e de reforço
Wang et al. Protein change of intestinal epithelial cells induced in vitro by Trichinella spiralis infective larvae
NO996514L (no) Overflateantigener og proteiner nyttige i sammensetninger for diagnose og forebygging av Lymesykdom
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
BR0113915A (pt) Uso de adenil ciclase da espécie bordetella, composição imunogênica ou farmacêutica, uso da mesma, e , vetor proteináceo
MX2022014249A (es) Composición farmacéutica para tratar el cáncer.
Wang et al. Commensals serve as natural barriers to mammalian cells during Acanthamoeba castellanii invasion
MX2022016587A (es) Bioconjugado tetravalente de shigella (shigella4v).